Drugs for COVID-19

The FDA has approved the complement C3 inhibitor pegcetacoplan (Syfovre – Apellis) for treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Given as a series of monthly or every-other-month (EOM) intravitreal injections, it is the first drug to become available for use in patients with atrophic dry AMD. Subcutaneous pegcetacoplan was approved earlier as Empaveli for treatment of paroxysmal nocturnal hemoglobinuria.

AGE-RELATED MACULAR DEGENERATION ― AMD has two major forms. The dry (non-neovascular) form occurs in about 90% of patients and is...  Continue reading

Coming Soon
Drugs for Common Respiratory Tract Infections
Altuviiio – A Longer-acting Factor VIII Product for Hemophilia A
Cyclosporine Ophthalmic Emulsion (Verkazia) for Vernal Keratoconjunctivitis
Cardiovascular Outcomes with Bempedoic Acid (Nexletol)